Ted Myles

Ted Myles has served as Chief Financial Officer & Head of Business Operations since July 2020. Prior to joining our executive team, Mr. Myles served as a member of our board of directors from November 2018 until July 2020. Mr. Myles most recently served as Chief Financial Officer and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a commercial-stage bio-pharmaceutical company.  Prior to AMAG, he served as Chief Financial Officer and Chief Operating Officer at Ocata Therapeutics, Inc. (acquired by Astellas), Chief Financial Officer and Vice President of Operations at PrimeraDx, Inc. (acquired by Qiagen), and Controller of EMD Pharmaceuticals (now EMD Serono, a part of Merck KGaA). Earlier in his career, Mr. Myles was an associate in the healthcare investment banking group at SG Cowen Securities Corporation and was a senior associate in the audit practice of Coopers & Lybrand LLP. Mr. Myles holds a M.B.A.  from John M. Olin School of Business at Washington University and B.S. in Business Administration from the University of Hartford.